BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 22208613)

  • 21. Smad4 deficiency substitutes Cdkn2b but not Cdkn2a downregulation in pancreatic cancer following induction of genetic events in adult mice.
    Jia X; Sun B; Tu Q; Qi H; Li L; Liu X; Yan L; Dai H; Kong Q; Tang C; Zhao X
    Pancreatology; 2021 Mar; 21(2):418-427. PubMed ID: 33483239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4.
    Hosoda W; Chianchiano P; Griffin JF; Pittman ME; Brosens LA; Noë M; Yu J; Shindo K; Suenaga M; Rezaee N; Yonescu R; Ning Y; Albores-Saavedra J; Yoshizawa N; Harada K; Yoshizawa A; Hanada K; Yonehara S; Shimizu M; Uehara T; Samra JS; Gill AJ; Wolfgang CL; Goggins MG; Hruban RH; Wood LD
    J Pathol; 2017 May; 242(1):16-23. PubMed ID: 28188630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
    Liao J; Chung YT; Yang AL; Zhang M; Li H; Zhang W; Yan L; Yang GY
    Mol Carcinog; 2013 Sep; 52(9):739-50. PubMed ID: 22549877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic alterations in pancreatic carcinoma.
    Schneider G; Schmid RM
    Mol Cancer; 2003 Jan; 2():15. PubMed ID: 12605716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells.
    Villanueva A; García C; Paules AB; Vicente M; Megías M; Reyes G; de Villalonga P; Agell N; Lluís F; Bachs O; Capellá G
    Oncogene; 1998 Oct; 17(15):1969-78. PubMed ID: 9788440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing.
    Yu J; Gemenetzis G; Kinny-Köster B; Habib JR; Groot VP; Teinor J; Yin L; Pu N; Hasanain A; van Oosten F; Javed AA; Weiss MJ; Burkhart RA; Burns WR; Goggins M; He J; Wolfgang CL
    Cancer Lett; 2020 Nov; 493():245-253. PubMed ID: 32896616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A.
    Tu Q; Hao J; Zhou X; Yan L; Dai H; Sun B; Yang D; An S; Lv L; Jiao B; Chen C; Lai R; Shi P; Zhao X
    Oncogene; 2018 Jan; 37(1):128-138. PubMed ID: 28892048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
    Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
    Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic ductal adenocarcinomas from Mexican patients present a distinct genomic mutational pattern.
    Sanchez P; Espinosa M; Maldonado V; Barquera R; Belem-Gabiño N; Torres J; Cravioto A; Melendez-Zajgla J
    Mol Biol Rep; 2020 Jul; 47(7):5175-5184. PubMed ID: 32583281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
    Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
    Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.
    Mohri D; Asaoka Y; Ijichi H; Miyabayashi K; Kudo Y; Seto M; Ohta M; Tada M; Tanaka Y; Ikenoue T; Tateishi K; Isayama H; Kanai F; Fukushima N; Tada M; Kawabe T; Omata M; Koike K
    J Gastroenterol; 2012 Feb; 47(2):203-13. PubMed ID: 22041919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy.
    Dudley JC; Zheng Z; McDonald T; Le LP; Dias-Santagata D; Borger D; Batten J; Vernovsky K; Sweeney B; Arpin RN; Brugge WR; Forcione DG; Pitman MB; Iafrate AJ
    J Mol Diagn; 2016 Jan; 18(1):124-30. PubMed ID: 26596524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
    Voutsadakis IA; Digklia A
    Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
    Dunne RF; Hezel AF
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
    Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
    Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes.
    Schlitter AM; Segler A; Steiger K; Michalski CW; Jäger C; Konukiewitz B; Pfarr N; Endris V; Bettstetter M; Kong B; Regel I; Kleeff J; Klöppel G; Esposito I
    Sci Rep; 2017 Feb; 7():41064. PubMed ID: 28145465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells.
    Peng B; Fleming JB; Breslin T; Grau AM; Fojioka S; Abbruzzese JL; Evans DB; Ayers D; Wathen K; Wu T; Robertson KD; Chiao PJ
    Clin Cancer Res; 2002 Nov; 8(11):3628-38. PubMed ID: 12429655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.